June 2014

FDA to Require Blood Clot Warnings on Testosterone Products

On June 20, 2014 the United States Food and Drug Administration announced that it would require the manufacturers of all approved testosterone products to include a warning in the drug labeling about the risk of blood clots in the veins, also known as venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE).

See the FDA announcement here.

Read more